Branimir I. Sikic
Affiliations: | 2002- | Medicine/Oncology | Stanford University School of Medicine, Palo Alto, CA, United States |
Google:
"Branimir Sikic"Mean distance: 18.08 (cluster 32)
Children
Sign in to add trainee| Kevin G. Chen | grad student | 1998-2002 | Stanford |
| Norman J. Lacayo | post-doc | Stanford Medical School | |
| Jean-Pierre Jaffrezou | post-doc | 1992-1995 | Stanford |
| Charles Dumontet | post-doc | 1993-1995 | Stanford |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chen KG, Duran GE, Mogul MJ, et al. (2020) Genomic stability at the coding regions of the multidrug transporter gene : insights into the development of alternative drug resistance mechanisms in human leukemia cells. Cancer Drug Resistance (Alhambra, Calif.). 3: 959-979 |
| Ansell SM, Flinn I, Taylor MH, et al. (2020) Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Advances. 4: 1917-1926 |
| Duran GE, Sikic BI. (2019) The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance. Plos One. 14: e0210879 |
| Marcelletti JF, Sikic BI, Cripe LD, et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry. Part B, Clinical Cytometry |
| Burris HA, Infante JR, Ansell SM, et al. (2017) Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016701508 |
| Duran GE, Wang YC, Moisan F, et al. (2017) Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. British Journal of Cancer |
| Dubey R, Lebensohn A, Bahrami-Nejad Z, et al. (2016) Chromatin-remodeling complex SWI/SNF controls multidrug resistance by transcriptionally regulating the drug efflux pump ABCB1. Cancer Research |
| Rosen LS, LoRusso P, Ma WW, et al. (2016) A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investigational New Drugs |
| Willis S, Villalobos VM, Gevaert O, et al. (2016) Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. Plos One. 11: e0149183 |
| Chao MP, McKenna KM, Cha A, et al. (2016) Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies Cancer Immunology Research. 4 |